NASA Funds Crew Concepts
Yesterday the Obama administration announced it’s 2010 budget for NASA, which scraps plans to return to the moon by 2020 and focuses on using commercial companies to ferry astronauts into orbit. NASA has wasted no time in pushing ahead with this plan, awarding $50 million to five different companies for the development of concepts and technology for human spaceflight.
The money was awarded through an open competition for funds from the American Reinvestment and Recovery Act of 2009. Blue Origin, based in Kent, WA, will receive $3.7 million; the Boeing Company of Houston will receive $18 million; Paragon Space Development Corporation of Tucson, AZ, will receive $1.4 million; Sierra Nevada Corporation, based in Louisville, CO, will receive $20 million; and United Launch Alliance of Centennial, CO, will received $6.7 million.
The awards are the first step in NASA’s investment in commercial human spaceflight. In 2008 the agency awarded Space Exploration Technologies (SpaceX) a $1.6 billion contract to provide a launch vehicle capable of reaching the space station. The contract was for a cargo-carrying spacecraft, with an option of developing a version for crew.
The White House’s initial budget proposal has allocated $500 million in 2011 financial year for commercial crew concepts, and $312 million for commercial cargo development. In the 2012 financial year commercial crew expenditure is expected to increase to $1.4 billion.
Keep Reading
Most Popular

Meta has built a massive new language AI—and it’s giving it away for free
Facebook’s parent company is inviting researchers to pore over and pick apart the flaws in its version of GPT-3

The gene-edited pig heart given to a dying patient was infected with a pig virus
The first transplant of a genetically-modified pig heart into a human may have ended prematurely because of a well-known—and avoidable—risk.

Saudi Arabia plans to spend $1 billion a year discovering treatments to slow aging
The oil kingdom fears that its population is aging at an accelerated rate and hopes to test drugs to reverse the problem. First up might be the diabetes drug metformin.

Yann LeCun has a bold new vision for the future of AI
One of the godfathers of deep learning pulls together old ideas to sketch out a fresh path for AI, but raises as many questions as he answers.
Stay connected

Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.